Inhibikase Therapeutics, Inc. Files Prospectus Supplement for At-the-Market Offering

Inhibikase Therapeutics, Inc. has filed a prospectus supplement dated December 19, 2025, for its existing "at the market offering" program. The company may offer and sell shares of its common stock with an aggregate offering price of up to $185,000,000. These shares will be offered and sold through Jefferies LLC as sales agent, pursuant to an Open Market Sale Agreement dated June 20, 2025. This filing is made under the company's existing registration statement on Form S-3, declared effective on June 27, 2025. The filing includes exhibits such as the Open Market Sale Agreement and a legal opinion from Goodwin Procter LLP regarding the validity of the shares to be issued. The company has elected to be treated as an emerging growth company and has not elected to extend the transition period for complying with new or revised financial accounting standards.